Research
Hormonal
The dual agonist tirzepatide has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.
Practitioners may consider tirzepatide as a more effective option for weight loss in obese patients.
StrongSupportsmedium confidence
The dual agonist tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.
Why this rating
Based on the review of pharmacotherapy strategies.
Source
Why does <scp>GLP</scp> ‐1 agonist combined with <scp>GIP</scp> and/or <scp>GCG</scp> agonist have greater weight loss effect than <scp>GLP</scp> ‐1 agonist alone in obese adults without type 2 diabetes?
Yuchen Jiang et al. · Diabetes Obesity and Metabolism · 2024
reviewCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →